US names 10 prescription drugs subject to price negotiations
Al JazeeraMove is expected to cut costs for some patients but faces lawsuits from drugmakers and heavy criticism from Republicans. US President Joe Biden’s administration has released a list of 10 prescription medicines that will be subject to the first-ever price negotiations by the United States Medicare health programme, a move that could affect tens of millions of people. Biden’s signature Inflation Reduction Act, signed into law in August last year, allows the health programme for Americans aged 65 and over to negotiate prices for some of its most costly drugs. Medicines on the list released by the White House on Tuesday morning include Merck & Co’s diabetes drug Januvia, Eliquis rival Xarelto from Johnson & Johnson and AbbVie’s leukaemia treatment Imbruvica. The White House said on Tuesday that the Medicare agency aims to negotiatiate prices for as many as 60 drugs over the next four years, followed by an additional 20 drugs every year after that.